GLP-1 Drugs Cut Addiction Risks
Dayton News Today | 2 Min News | The Daily News Now! · The Daily News Now!
Audio is streamed directly from the publisher (api.fastcast.ai) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
GLP-one drugs like Ozempic and Wegovy, initially developed for diabetes and weight loss, are showing promising results in reducing substance use disorders. A study of over six hundred thousand veterans found that those on GLP-one drugs had significantly lower rates of deaths from substance use, overdoses, and suicide attempts. These drugs work by dampening dopamine signals in the brains reward centers, making addictive substances less appealing. Real-world impact includes reduced serious events in those already battling addiction and prevention of new addictions in those without prior issues. Other research supports these findings, with Swedish studies showing reduced alcohol hospitalizations and human trials showing less craving and drinking. With millions already using these drugs, they could revolutionize addiction care by targeting cravings across substances.
Support the show:
Get a discount at https://solipillow.com/discount/dnn.
Advertise on DNN:
[email protected]
This is an automated, high-level news summary based on public reporting.
Report issues to [email protected].
View sources & latest updates:
https://sources.thednn.ai/fb18aa218762ae41